Black Diamond Therapeutics earnings were -$43.2M for the trailing 12 months ending Mar 31, 2026, with N/A growth year over year. The latest BDTX earnings report on Mar 31, 2026 announced Q1 2026 earnings of -$9.0M, down 40.2% from last quarter. For the last reported fiscal year 2025 ending Dec 31, 2025, BDTX reported annual earnings of $22.4M, with -132.1% growth.
Black Diamond Therapeutics Earnings Reports & History FAQ
What were Black Diamond Therapeutics's earnings last quarter?
On BDTX's earnings call on Invalid Date, Black Diamond Therapeutics (NASDAQ: BDTX) reported Q1 2026 earnings per share (EPS) of -$0.16, up 116% year over year. Total BDTX earnings for the quarter were -$9.04 million. In the same quarter last year, Black Diamond Therapeutics's earnings per share (EPS) was $1.00.
Is Black Diamond Therapeutics profitable or losing money?
As of the last Black Diamond Therapeutics earnings report, Black Diamond Therapeutics is currently losing money. Black Diamond Therapeutics's net profit (also called net income) for the twelve months ending Mar 31, 2026 was -$43.21 million, a 948.77% decrease year over year.
What was BDTX's earnings growth in the past year?
As of Black Diamond Therapeutics's earnings date in Invalid Date, Black Diamond Therapeutics's earnings has grown year over year. BDTX earnings in the past year totalled -$43.21 million.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.